Webinar | October 26, 2021

ICH E9(R1) Addendum On Estimands And Sensitivity Analysis

Source: OCT Clinical

The European Medicines Agency (EMA) adopted the E9(R1) addendum on estimands and sensitivity analysis in clinical trials effective July 30 2020. Bringing clarity to the concept of estimands and the key issues debated in E9(R1) will help to understand their purpose and impact on study design, statistical analyses and the study outcome.

Discover how the new framework will improve the way of designing and planning clinical trials and performing primary analyses and sensitivity analyses.

The webinar is hosted by Kristina Bondareva, the Head of Biostatistics at OCT Clinical. 

VIEW THE WEBINAR!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader